Roche
Roche’s influenza drug Xofluza gets EU approval
January 11, 2021Sales and Marketing EC, Roche, influenza
The European Commission (EC) has approved Roche’s Xofluza (baloxavir marboxil) for the treatment of uncomplicated influenza in patients aged 12 …
Roche secures emergency FDA approval for COVID-19 antibody test
December 3, 2020Sales and Marketing COVID-19, FDA, Roche
The FDA has awarded Emergency Use Authorization to Roche’s COVID-19 test to allow users in the US to analyse the …
FDA greenlights Gavreto for advanced or metastatic rearranged during transfection (RET)-mutant medullary thyroid cancer in over-12s
December 2, 2020Research and Development, Sales and Marketing FDA, Gavreto, Roche
The FDA has awarded accelerated approval to Roche and Blueprint Medicines’ Gavreto (pralsetinib) for the treatment of advanced or metastatic …
FDA approves Venclexta combo in acute myeloid leukaemia, despite it missing main study goal
October 19, 2020Sales and Marketing AbbVie, FDA, Roche, Venclexta, pharma
The FDA has given approval to AbbVie and Roche’s jointly-developed BCL-2 inhibitor Venclexta (venetoclax) in combination with azacitidine, decitabine, or low-dose …
Judge allows $1.5 billion Tamiflu stockpiling lawsuit against Roche to go ahead
September 30, 2020Research and Development Roche, Tamiflu
A Maryland federal judge denied Roche’s motion to throw out a lawsuit that alleges the company defrauded the US and …
Roche says its rheumatoid arthritis drug reduces the need for ventilators in coronavirus patients
September 18, 2020Medical Communications COVID-19, Roche
Roche says that its Actermra/Roactemra drugs reduce the likelihood that coronavirus patients with virus-related pneumonia will need to be put …
Roche to start new trials of Ocrevus to defend multiple sclerosis franchise
September 9, 2020Research and Development MS, MS drug, Roche
Roche is to begin expanding trials of Ocrevus in multiple sclerosis (MS) patients to defend its MS franchise from its …
China approves its first biosimilar of Roche’s Herceptin in HER2+ cancers
August 18, 2020Manufacturing and Production, Sales and Marketing China, Henlius, Herceptin, Roche, biosimilar
China’s National Medical Products Administration (NMPA) has given the green light to Shanghai’s Henlius for its biosimilar version of Roche’s …
Roche’s entrolizumab disappoints at Phase 3 in moderately to severely active ulcerative colitis
August 11, 2020Manufacturing and Production, Research and Development Roche, etrolizumab, trial failure, ulcerative colitis
Roche has voiced its disappointment after its investigational therapy etrolizumab showed “mixed results” as a treatment for moderately to severely …
Genentech’s Evrysdi becomes first FDA-approved oral treatment for spinal muscular atrophy
August 10, 2020Sales and Marketing Evrysdi, FDA, Genentech, Roche, spinal muscular atrophy
Genentech’s Evrysdi (risdiplam) has secured FDA approval for the treatment of spinal muscular atrophy (SMA), making it the first oral therapy …
Top Ten most popular articles on Pharmafile.com this week
July 31, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing COVID-19, Roche, UK government, Vaccine, lilly, pharma, top 10
Another week dominated by COVID-19. Among our most popular stories this week, Celltrion’s infliximab biosimilar Remsima has scored approval for …
UCB syncs up with Roche and Genentech in Alzheimer’s drug deal worth a potential $2bn+
July 30, 2020Research and Development, Sales and Marketing Genentech, Roche, UCB, partnership
UCB Pharma is set to partner up with Roche and Genentech in a development and commercialisation deal focused on its …
Roche’s Actemra fails to improve clinical status in COVID-19-associated pneumonia
July 29, 2020Research and Development Actemra, COVID-19, Roche, pharma
Roche has announced the disappointing news that its therapy Actemra/RoActemra (tocilizumab) failed to improve clinical status to a statistically significant …
Roche and Blueprint extend collaboration with $1.7 billion cancer drug development and commercialisation deal
July 14, 2020Manufacturing and Production, Research and Development Blueprint Medicines, Cancer, Roche, pralsetinib
Roche and Blueprint Medicines have come together in a $1.7 billion development and commercialisation partnership focused on precision therapy pralsetinib …
Roche’s Tecentriq fails to hit main Phase 3 goal in front-line ovarian cancer
July 13, 2020Research and Development, Sales and Marketing Genentech, Roche, ovarian cancer, tecentriq
Roche subsidiary Genentech has revealed that its immunotherapy Tecentriq (atezolizumab), combined with Avastin (bevacizumab), paclitaxel and carboplatin, fell short of …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
